FierceBiotech |
Drayson remote monitoring app misses endpoint in gestational diabetes trial
FierceBiotech Drayson Health's digital remote management app has failed to improve mean blood glucose level in women with gestational diabetes. The primary endpoint miss was the headline detail in a mixed set of data on the GDm-Health app. Investigators enrolled 203 … |
Discussion
Comments are disallowed for this post.
Comments are closed.